Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Revenue of Vaccinex, Inc. (VCNX)
Revenue in 2023 (TTM): $570 K
According to Vaccinex, Inc.'s latest financial reports the company's current revenue (TTM) is $570 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Vaccinex, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $570 K | $-16,004,000 | $-19,748,000 | $-20,251,000 | $-20,251,000 |
| 2022 | $100 K | $-107,000 | $-19,606,000 | $-19,815,000 | $-19,722,000 |
| 2021 | $900 K | $731 K | $-21,402,000 | $-22,380,000 | $-23,232,000 |
| 2020 | $50 K | $48 K | $-28,055,000 | $-28,851,000 | $-29,309,000 |
| 2019 | $523 K | $324 K | $-31,614,000 | $-31,863,000 | $-32,015,000 |
| 2018 | $724 K | $-309,000 | $-28,903,000 | $-29,518,000 | $-29,518,000 |
| 2017 | $90 K | $-70,000 | $-17,195,000 | $-18,759,000 | $-18,722,000 |
| 2016 | $316 K | $201 K | $-10,775,000 | $-13,943,000 | $-13,943,000 |